Vaccines pp 357-396 | Cite as

Designing a Vaccine Against HIV

  • A. M. Schultz
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 133)


The viral cause of AIDS was not established until 1983 (BARRE-SINNOUSSI et al. 1983; GALLO et al. 1983; LEVY et al. 1984), although HIV could have existed in the human population for 50–200 years previously (LI et al. 1988; SMITH et al. 1988; Yokoyama et al. 1988) and may have found its way to Europe and North America as early the 1960s (CORBITT et al. 1990; GARRY et al. 1988; HUMINER et al. 1987). The epidemic continues to sweep across the world, making its most recent inroads in Asia (MANN and TARANTOLA 1996). Vaccines to prevent other viral diseases have been highly successful (PLOTKIN and MORTIMER 1994), and enthusiasm for obtaining one to contain AIDS, once HIV was identified as its cause, was high (RUSSELL 1984). Others pointed out apparently daunting obstacles (ADA 1988; COHN and STEINMAN 1988; FERDINAND et al. 1987; LEVY 1988; NATHANSON and GONZALES-SCARANO 1989), and the intervening years have seen swings of optimism and pessimism about a timetable for eventual success.


Human Immunodeficiency Virus Human Immunodeficiency Virus Type Human Immunodeficiency Virus Infection Acquire Immune Deficiency Syndrome Simian Immunodeficiency Virus 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ada G (1988) Prospects for HIV vaccines. J Acquir Immune Defic Syndr Hum Retrovirol 1:295–303Google Scholar
  2. Ahmad S, Yilma T, Luciw PA et al (1994) Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res Hum Retroviruses 10:195–204PubMedGoogle Scholar
  3. Alcabes P, Munoz A, Vlahov D, Friedland GH (1993) Incubation period of human immunodeficiency virus. Epidemiol Rev 15:303–318PubMedGoogle Scholar
  4. Almond N, Rose J, Sangster R et al (1997) Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. J Gen Virol 78:1919–1922PubMedGoogle Scholar
  5. Altman JD, Moss PAH, Goulder PJR et al (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94–96PubMedGoogle Scholar
  6. Altman LK (1998) FDA authorizes first full testing of HIV vaccine. The New York Times, 4 June 1998, p 1Google Scholar
  7. Anderson MJ, Porter DC, Moldoveanu Z et al (1997) Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins. AIDS Res Hum Retroviruses 13:53–62PubMedGoogle Scholar
  8. Andersson S, Makitalo B, Thorstensson R et al (1996) Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis 174:977–985PubMedGoogle Scholar
  9. Andre S, Seed B, Eberle J et al (1998) Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72:1497–1503PubMedGoogle Scholar
  10. Andrus L, Prince AM, Bernal I et al (1998) Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL- SCID mice:isolation of a neutralization escape variant. J Infect Dis 177:889–897PubMedGoogle Scholar
  11. Asjo B, Morfeldt-Manson L, Albert J et al (1986) Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986:660–662Google Scholar
  12. Baba TW, Ruprecht RM, Greene MF et al (1995) Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820–1825PubMedGoogle Scholar
  13. Bachmann MF, Zinkernagel RM (1996) The influence of virus structure on antibody responses and virus serotype formation. Immunol Today 17:553–558PubMedGoogle Scholar
  14. Barker E, Bossart KN, Levy JA (1998) Primary CD8+ cells from HIV-infected individuals can suppress productive infection of macrophages independent of beta-chemokines. Proc Natl Acad Sci USA 95:1725–1729PubMedGoogle Scholar
  15. Barre-Sinnoussi F, Chermann JC, Rey F et al (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868–871Google Scholar
  16. Barry MA, Lai WC, Johnston SA (1995) Protection against mycoplasma infection using expression-library immunization. Nature 377:632–635PubMedGoogle Scholar
  17. Baum LL, Cassutt KJ, Knigge K et al (1996) HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 157:2168–2173PubMedGoogle Scholar
  18. Beddows S, Louisirirotchanakul S, Cheingsong-Popov R et al (1998) Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1:role of V3-specific antibodies. J Gen Virol 79:77–82PubMedGoogle Scholar
  19. Belshe RB, Clements ML, Dolin R et al (1993) Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. J Infect Dis 168:1387–1395PubMedGoogle Scholar
  20. Belshe RB, Graham BS, Keefer MC et al (1994) Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 272:475–480PubMedGoogle Scholar
  21. Belyakov IM, Derby MA, Ahlers JD et al (1998) Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci USA 95:1709–1714PubMedGoogle Scholar
  22. Benjouad A, Gluckman JC, Rochat H et al (1992) Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160. J Virol 66:2473–2283PubMedGoogle Scholar
  23. Benson J, Franchini G, Tartaglia J et al (1998) Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251):dependence on route of challenge exposure. J Virol 72:4170–4182PubMedGoogle Scholar
  24. Beretta A, Furci L, Burastero S et al (1997) HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection. Immunol Lett 51:39–43Google Scholar
  25. Berger E A (1997) HIV entry and tropism:the chemokine receptor connection. AIDS 11[Suppl A]:S3–16PubMedGoogle Scholar
  26. Berger EA, Doms RW, Fenyo EM et al (1998) A new classification for HIV-1 (letter). Nature 391:240PubMedGoogle Scholar
  27. Betts MR, Krowka J, Santamaria C et al (1997) Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians J Virol 71:8908–8911Google Scholar
  28. Biberfield G, Putkonen P, Thorstensson R, Norrby E (1992) Prevention of HIV-2 and SIVSM infection in cynomolgus monkeys by active or passive immunization AIDS Res Hum Retroviruses 8:1511–1513PubMedGoogle Scholar
  29. Blackbourn DJ, Mackewicz CE, Barker E et al (1996) Suppression of HIV replication by lymphoid tissue CD8+ cells correlates with the clinical state of HIV-infected individuals. Proc Natl Acad Sci USA 93:13125–13130PubMedGoogle Scholar
  30. Blazevic V, Ranki A, Krohn KJ (1995) Helper and cytotoxic T cell responses of HIV type 1-infected individuals to synthetic peptides of HIV type 1 Rev. AIDS Res Hum Retroviruses 11:1335–1342Google Scholar
  31. Bonhoeffer S, May RM, Shaw GM, Nowak MA (1997) Virus dynamics and drug therapy. Proc Natl Acad Sci USA 94:6971–6976PubMedGoogle Scholar
  32. Boots LJ, McKenna PM, Arnold BA et al (1997) Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries. AIDS Res Hum Retroviruses 13:1549–1559PubMedGoogle Scholar
  33. Borrow P, Lewicki H, Wei X et al (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3:205–211PubMedGoogle Scholar
  34. Bou-Habib DC, Roderiquez G, Oravecz T et al (1994) Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 68:6006–6013PubMedGoogle Scholar
  35. Boyer JD, Ugen KE, Wang B et al (1997) Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 3:526–532PubMedGoogle Scholar
  36. Buchbinder SP, Katz MH, Hessol NA et al (1994) Long-term HIV-1 infection without immunologic progression. AIDS 8:1123–1128PubMedGoogle Scholar
  37. Burton DR, Montefiori DC (1997) The antibody response in HIV-1 infection. AIDS 11[Suppl A]:S87–S98PubMedGoogle Scholar
  38. Carlson JR, McGraw TP, Keddie E et al (1990) Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum Retroviruses 6:1239–1246PubMedGoogle Scholar
  39. Cao H, Kanki P, Sankale JL et al (1997) Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades:implications for vaccine development. J Virol 71:8615–8623PubMedGoogle Scholar
  40. Centers for Disease Control (1986) Current trends poliomyelitis - United States 1975-1984. MMWR 35:180–182Google Scholar
  41. Chanh TC, Dreesman GR, Kanda P et al (1986) Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J 5:3065–3071PubMedGoogle Scholar
  42. Choppin J, Guillet JG, Levy JP (1992) HLA class I binding regions of HIV-1 proteins Crit Rev Immunol 12:1–16Google Scholar
  43. Clements JE, Montelaro RC, Zink MC et al (1995) Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 69:2737–2744PubMedGoogle Scholar
  44. Clements ML (1997) Clinical trials of human immunodeficiency virus vaccines. In:DeVita VT Jr, Hellman S, Rosenberg SA (eds) AIDS:biology, diagnosis, treatment and prevention chap 32.2, 4th edn. Lippincott-Raven, Philadelphia, pp 617–626Google Scholar
  45. Clements-Mann ML, Weinhold K, Matthews TJ et al (1998) Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 177:1230–1246PubMedGoogle Scholar
  46. Clerici M, Shearer GM (1994) The Th1-Th2 hypothesis of HIV infection:new insights Immunol Today 15:575–581Google Scholar
  47. Clerici M Giorgi JV, Chou CC et al (1992) Cell-mediated immune response to human immuno-deficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 165:1012–1019PubMedGoogle Scholar
  48. Cocchi F, DeVico AL, Garzino-Demo A et al (1995) Identification of RANTES MIP- 1 alpha and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ Tcells. Science 270:1811–1815PubMedGoogle Scholar
  49. Cohen J (1993) Jitters jeopardize AIDS vaccine trials. Science 262:980–981PubMedGoogle Scholar
  50. Cohen J (1997) Novel campaign to test live HIV vaccine. Science 277:1035PubMedGoogle Scholar
  51. Cohn ZA, Steinman RM (1988) The immunological and infectious sequelae of the acquired immune deficiency syndrome. J Exp Med 168:2415–2423PubMedGoogle Scholar
  52. Conley AJ, Kessler JA Jr, Boots LJ et al (1994) Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM41-2F5 an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 91:3348–3352PubMedGoogle Scholar
  53. Conley AJ Murthy KK, Rouse SR et al (1996) The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 70:6751–6758PubMedGoogle Scholar
  54. Connick E Marr DG, Zhang XQ et al (1996) HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retroviruses 12:1129–1140PubMedGoogle Scholar
  55. Corbitt G, Williams G, Bailey AS (1990) HIV infection in Manchester, 1959. Lancet336:51PubMedGoogle Scholar
  56. Cranage MP Hall GA, Dennis MJ et al (1997) Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 229:143–154PubMedGoogle Scholar
  57. Dalgleish AG, Chanh TC, Kennedy RC et al (1988) Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 165:209–215PubMedGoogle Scholar
  58. Daniel MD, Mazzara GP, Simon MA et al (1994) High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res Hum Retroviruses 10:839–851PubMedGoogle Scholar
  59. Davis HL McCluskie MJ, Gerin JL, Purcell RH (1996) DNA vaccine for hepatitis B:evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci USA 93:7213–7218PubMedGoogle Scholar
  60. Deacon NJ Tsykin A, Solomon A et al (1995) Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270:988–991PubMedGoogle Scholar
  61. Deng H Liu R, Ellmeier W et al (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661–666PubMedGoogle Scholar
  62. Deprez B, Sauzet JP, Boutillon C et al (1996) Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine 14:375–382PubMedGoogle Scholar
  63. Desrosiers RC (1994) Controversies in science:yes, it is time to consider use of a live-attenuated virus vaccine against HIV-1. J NIH Res 6:54–60Google Scholar
  64. Dolin R (1995) Human studies in the development of human immunodeficiency virus vaccines. J Infect Dis 172:1175–1183PubMedGoogle Scholar
  65. Dolin R, Graham BS, Greenberg SB et al (1991) The safety and immunogemcity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med 114:119–127PubMedGoogle Scholar
  66. Dragic T Litwin V, Allaway GP et al (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667–673PubMedGoogle Scholar
  67. D’Souza MP, Livnat D, Bradac JA, Bridges SH (1997) Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays:performance criteria for selecting candidate antibodies for clinical trials. J Infect Dis 175:1056–1062PubMedGoogle Scholar
  68. Durali D, Morvan J, Letourneur F et al (1998) Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J Virol 72:3547–3553PubMedGoogle Scholar
  69. Egan MA, Pavlat WA, Tartaglia J et al (1995) Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis 171:1623–1627PubMedGoogle Scholar
  70. Emini EA, Schlief WA, Nunberg JH et al (1992) Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728–730PubMedGoogle Scholar
  71. Fenyo EM, Morfeldt-Manson L, Chiodi F et al (1988) Distinct replicative and cyto- pathic characteristics of human immunodeficiency virus isolates. J Virol 62:4414–4419PubMedGoogle Scholar
  72. Ferdinand FJ, Dorner F, Kurth R (1987) Perspectives of HIV vaccine developments. J Virol Methods 17:63–67PubMedGoogle Scholar
  73. Ferrari G, Humphrey W, McElrath MJ et al (1997) Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 94:1396–1401PubMedGoogle Scholar
  74. Fowke KR, Plummer FA, Ngugi EN et al (1996) Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 348:1347–1351PubMedGoogle Scholar
  75. Frey A, Neutra MR, Robey (1997) Peptomer aluminum oxide nanoparticle conjugates as systemic and mucosal vaccine candidates:synthesis and characterization of a conjugate derived from the C4 domain of HIV-1MN gp120. Bioconjug Chem 8:424–433PubMedGoogle Scholar
  76. Fuller DH, Corb MM, Barnett S et al (1997) Enhancement of immunodeficiency virus- specific immune responses in DNA-immunized rhesus macaques. Vaccine 15:924–926PubMedGoogle Scholar
  77. Furci L, Scarlatti G, Burastero S et al (1997) Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med 186:455–460PubMedGoogle Scholar
  78. Gallimore A, Stott J, Corcoran T et al (1995) Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nat Med 1:1167–1173PubMedGoogle Scholar
  79. Gallo RC, Sarin PC, Gelmann EP et al (1983) Isolation of human T-cell leukemia virus in acquired immunodeficiency syndrome (AIDS). Science 220:865–867PubMedGoogle Scholar
  80. Gange SJ, Munoz A, Schrager LK et al (1997) Design of nested studies to identify factors related to late progression to HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 15[Suppl 1]:S5–S9Google Scholar
  81. Gardner M, Rosenthal A, Jennings M et al (1995) Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res Hum Retroviruses 11:843–854PubMedGoogle Scholar
  82. Garry RF, Drake WL Jr, Cole WR et al (1988) Documentation of an AIDS virus infection in the United States in 1968. JAMA 260:2085–2087PubMedGoogle Scholar
  83. Gauduin MC, Parren PW, Weir R et al (1997) Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 3:1389–1393PubMedGoogle Scholar
  84. Gibbs CJ Jr, Peters R, Gravell M et al (1991) Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees. Proc Natl Acad Sci USA 88:3348–3352PubMedGoogle Scholar
  85. Girard M, Fultz P, Barre-Sinnoussi F et al (1993) Further studies on HIV-1 vaccine protection in chimpanzees. In:Girard M, Valette L (eds) Retroviruses of human AIDS and related animal diseases:8e Colloque des “Cent Gardes.” Fondation Marcel Merieux, Lyon, France, pp 139–143Google Scholar
  86. Girard M, Yue L, Barre-Sinoussi F et al (1996) Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain. J Virol 70:8229–8233Google Scholar
  87. Goldstein G (1996) HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 2:960–964PubMedGoogle Scholar
  88. Gorse GJ, Rogers JH, Perry JE et al (1995) HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. Vaccine 13:209–214PubMedGoogle Scholar
  89. Gorse GJ Keefer MC, Belshe RB et al (1996) A dose-ranging study of a prototype synthetic HIV-1 MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 173:330–339PubMedGoogle Scholar
  90. Gorse GJ, McElrath MJ, Matthews TJ et al (1998) Modulation of immunologic responses to HIV-1 MN recombinant gp160 vaccine by dose and schedule of administration. Vaccine 16:493–506PubMedGoogle Scholar
  91. Goulder PJ, Phillips RE, Colbert RA et al (1997a) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 3:212–217Google Scholar
  92. Goulder P, Price D, Nowak M et al (1997b) Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses. Immunol Rev 159:17–29Google Scholar
  93. Graham BS (1994) Serological responses to candidate AIDS vaccines. AIDS Res Hum Retroviruses 10:S145–S148PubMedGoogle Scholar
  94. Graham BS Belshe RB, Clements ML et al (1992) Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded controlled, randomized clinical trial. J Infect Dis 166:244–252PubMedGoogle Scholar
  95. Graham BS, Matthews TJ, Belshe RB et al (1993) Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 167:533–537PubMedGoogle Scholar
  96. Graham BS, Keefer MC, McElrath MJ et al (1996) Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults:recombinant glycoprotein (rgp)120. A randomized, double-blind trial. Ann Intern Med 125:270–279PubMedGoogle Scholar
  97. Gulick RM, Mellors JW, Havlir D et al (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337:734–739PubMedGoogle Scholar
  98. Haas G, Hosmalin A, Hadida F et al (1997) Dynamics of HIV variants and specific cytotoxic T-cell recognition in nonprogressors and progressors. Immunol Lett 57:63–68PubMedGoogle Scholar
  99. Hammer SM, Squires KE, Hughes MD et al (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337:725–733.PubMedGoogle Scholar
  100. Hasenkrug KJ Chesebro B (1997) Immunity to retroviral infection:the Friend virus model. Proc Natl Acad Sci USA 94:7811–7816PubMedGoogle Scholar
  101. Haynes JR, Cao SX, Rovinski B et al (1991) Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines. AIDS Res Hum Retroviruses 7:17–27PubMedGoogle Scholar
  102. Haynes BF, Torres JV, Langlois AJ et al (1993) Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. J Immunol 151:1646–1653PubMedGoogle Scholar
  103. Henderson LE, Sowder R, Copeland TD et al (1987) Direct identification of class II histocompati-bility DR proteins in preparations of human T-cell lymphotropic virus type III. J Virol 61:629–632PubMedGoogle Scholar
  104. Hinkula J, Svanholm C Schwartz S et al (1997) Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol 71:5528–5539PubMedGoogle Scholar
  105. Hirsch VM, Lifson JD, Moss B et al (1996) Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SlV)-infected macaques:effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 70:3741–3752PubMedGoogle Scholar
  106. Ho DD, Sarngadharan MG, Hirsch MS et al (1987) Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol 61:2024–2028PubMedGoogle Scholar
  107. Ho DD, Neumann AU, Perelson AS et al (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123–126PubMedGoogle Scholar
  108. Hoffman SL, Crutcher JM, Puri SK et al (1997) Sterile protection of monkeys against malaria after administration of interleukin-12. Nat Med 3:80–83PubMedGoogle Scholar
  109. Huminer D, Rosenfeld JB, Pitlik SD (1987) AIDS in the pre-AIDS era. Rev Infect Dis 9:1102–1108PubMedGoogle Scholar
  110. Ishii N, Fukushima J, Kaneko T et al (1997) Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 13:1421–1428PubMedGoogle Scholar
  111. Ivey-Hoyle M, Culp JS, Chaikin MA et al (1991) Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4. Proc Natl Acad Sci USA 88:512–516PubMedGoogle Scholar
  112. Jansson M, Popovic M, Karlsson A et al (1996) Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci USA 93:15382–15387PubMedGoogle Scholar
  113. Jassoy C, Walker BD (1997) HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. Springer Semin Immunopathol 18:341–354PubMedGoogle Scholar
  114. Johnson PR, Montefiori DC, Goldstein S et al (1992) Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc Natl Acad Sci USA 89:2175–2179PubMedGoogle Scholar
  115. Jones DH, Corris S, McDonald S et al (1997) Poly(DL-lactide-co-glycolide)- encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 15:814–817PubMedGoogle Scholar
  116. Kahn JO, Stites DP, Scillian J et al (1992) A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects. AIDS Res Hum Retroviruses 8:1321–1325PubMedGoogle Scholar
  117. Kahn JO, Sinangil F, Baenziger J et al (1994) Clinical and immunologic responses to human immuno-deficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidyl- ethanolamine in non-HIV-infected human volunteers. J Infect Dis 170:1288–1291PubMedGoogle Scholar
  118. Kalams SA, Buchbinder SP, Billingsley JM et al (1998) Coordinate control of HIV replication mediated by CD4 and CD8 cells, (submitted)Google Scholar
  119. Kannagi M, Chalifoux LV, Lord CI, Letvin NL (1988) Suppression of simian immuno-deficiency virus replication in vitro by CD8+ lymphocytes. J Immunol 140:2237–2242PubMedGoogle Scholar
  120. Keefer MC, Graham BS, McElrath MJ et al (1996) Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. AIDS Res Hum Retroviruses 12:683–693PubMedGoogle Scholar
  121. Kelleher AD, Emery S, Cunningham P et al (1997) Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection. AIDS Res Hum Retroviruses 13:29–32PubMedGoogle Scholar
  122. Kent KA, Kitchin P, Mills KH et al (1994) Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251. AIDS Res Hum Retroviruses 10:189–194PubMedGoogle Scholar
  123. Kent SJ, Greenberg PD, Morton WR et al (1996) Detection of simian immunodefi-ciency virus (SlV)-specific CD8+ T-cells in macaques protected from SIV challenge by prior SIV subunit vaccination. J Virol 70:4941–4947PubMedGoogle Scholar
  124. Kessler JA Jr, McKenna PM, Emini EA et al (1997) Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 13:575–582PubMedGoogle Scholar
  125. Kim JJ. Trivedi NN, Nottingham LK et al (1998) Modulation of amplitude and direction of in vivo immune response by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 28:1089–1103PubMedGoogle Scholar
  126. Kirchhoff F, Greenough TC, Brettler DB et al (1995) Brief report:absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332:228–232PubMedGoogle Scholar
  127. Klavinskis LS, Gao L, Barnfield C et al (1997) Mucosal immunization with DNA-liposome complexes. Vaccine 15:818–820PubMedGoogle Scholar
  128. Koenig S, Fuerst TR, Wood LV et al (1990) Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein, J Immunol 145:127–135PubMedGoogle Scholar
  129. Koenig S, Conley AJ, Brewah YA et al (1995) Transfer of HIV-1 specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1:330–336PubMedGoogle Scholar
  130. Korber BT, Osmanov S, Esparza J, Myers G (1994) The World Health Organization Global Programme on AIDS proposal for standardization of HIV sequence nomenclature. WHO Network for HIV Isolation and characterization. AIDS Res Hum Retroviruses 10:1355–1358PubMedGoogle Scholar
  131. Kovacs JA, Vasudevachari MB, Easter M et al (1993) Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV seronegative volunteers by immunization with recombinant gp160. J Clin Invest 92:919–928PubMedGoogle Scholar
  132. Kwong PD, Wyatt R, Robinson J, et al (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648–659PubMedGoogle Scholar
  133. LaCasse RA, Follis KE, Moudgil T et al (1998) Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity, J Virol 72:2491–2495PubMedGoogle Scholar
  134. Langlois AJ, Weinhold KJ, Matthews TJ et al (1992) The ability of certain SIV vaccines to provoke reactions against normal cells. Science 255:292–293PubMedGoogle Scholar
  135. Learmont J, Tindall B, Evans L et al (1992) Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 340:863–867PubMedGoogle Scholar
  136. Le Grand R, Vogt G, Vaslin B et al (1996) Specific and non-specific immunity and protection of macaques against SIV infection. Vaccine 10:873–879Google Scholar
  137. Lechner T, Wang Y, Cranage M et al (1996) Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 2:767–775Google Scholar
  138. Letvin NL, Montefiori DC, Yasutomi Y et al (1997) Potent, protective anti-HIV immune response generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 94:9378–9383PubMedGoogle Scholar
  139. Levinson SO, Milzer A, Shaugnessy HJ et al (1954) Studies on production of antipoliomyelitis serum in rabbits. Proc Soc Exp Biol Med 87:111–114PubMedGoogle Scholar
  140. Levy JA (1988) Mysteries of HIV:challenges of therapy and prevention. Nature 333:519–522PubMedGoogle Scholar
  141. Levy JA, Hoffman AD, Kramer S et al (1984) Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225:840–842PubMedGoogle Scholar
  142. Li A, Katinger H, Posner MR et al (1998) Synergistic neutralization of simian-human immune-deficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J Virol 72:3235–3240PubMedGoogle Scholar
  143. Li WH, Tanimura M, Sharp PM (1988) Rates and dates of divergence between AIDS virus nucleotide sequences. Mol Biol Evol 5:313–330PubMedGoogle Scholar
  144. Lieberman J, Fabry JA, Fong DM et al (1997) Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocytes response to HIV type 1 in an infected individual. AIDS Res Hum Retroviruses 13:383–392PubMedGoogle Scholar
  145. Limbach KJ, Paoletti E (1996) Non-replicating expression vectors:applications in vaccine development and gene therapy. Epidemiol Infect 116:244–252Google Scholar
  146. Lipford GB, Bauer M, Blank C et al (1997) CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen:a new class of vaccine adjuvants. Eur J Immunol 27:2340–2344PubMedGoogle Scholar
  147. Lohman BL, Miller CJ, McChesney MB (1995) Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques. J Immunol 155:5855–5860PubMedGoogle Scholar
  148. Lu M, Kim PS (1997) A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn 15:465–471PubMedGoogle Scholar
  149. Lu S, Arthos J, Montefiori DC et al (1996) Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 70:3978–3991PubMedGoogle Scholar
  150. Lu Y, Salvato MS, Pauza CD et al (1996) Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J Acquir Immune Defic Syndr Hum Retrovirol 12:99–106PubMedGoogle Scholar
  151. Lubeck MD, Natuk R, Myagkikh M et al (1997) Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 3:651–658PubMedGoogle Scholar
  152. Lubaki NM, Ray SC, Dhruva B et al (1997) Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in persons without clinical progression. J Infect Dis 175:1360–1367PubMedGoogle Scholar
  153. Lyerly HK, Reed DL, Matthews TJ et al (1987) Anti-gp120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses 3:409–422PubMedGoogle Scholar
  154. Mackewicz CE, Ortega HW, Levy JA (1991) CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 87:1462–1466PubMedGoogle Scholar
  155. Macklin MD, McCabe D, McGregor MW et al (1998) Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J Virol 72:1491–1466PubMedGoogle Scholar
  156. Mann JM, Tarantola DJM (1995) AIDS in the World II. Oxford University Press, New York, pp 5–40Google Scholar
  157. Marthas ML, Miller CJ, Sutjipto S et al (1992) Efficacy of live-attenuated and whole- inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J Med Primatol 21:99–107PubMedGoogle Scholar
  158. Martinon F, Gras-Masse H, Boutillon C et al (1992) Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/ c mice to human immunodeficiency virus envelope glycoprotein. J Immunol 149:3416–3422PubMedGoogle Scholar
  159. Mascola JR, Louder MK, Surman SR et al (1996a) Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 12:1319–1328Google Scholar
  160. Mascola JR, Snyder SW, Weislow OS et al (1996b) Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 173:340–348Google Scholar
  161. Mascola JR, Louder MK, van Cott TC et al (1997) Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol 71:7198–7206PubMedGoogle Scholar
  162. Matsushita S, Robert-Guroff M, Rusche J et al (1988) Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol 62:2107–2114PubMedGoogle Scholar
  163. Mazzoli S, Trabattoni D, Lo Caputo S et al (1997) HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 3:1250–1257PubMedGoogle Scholar
  164. McElrath MJ, Corey L, Greenberg PD et al (1994) Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals. AIDS Res Hum Retroviruses 10[Suppl 2]:S69–S72PubMedGoogle Scholar
  165. McMichael A J, Phillips RE (1997) Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 15:271–296PubMedGoogle Scholar
  166. Mellors JW, Munoz A, Giorgi JV et al (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126:946–954PubMedGoogle Scholar
  167. Meng L, Ely JJ, Stouffer RL, Wolf DP (1997) Rhesus monkeys produced by nuclear transfer. Biol Reprod 57:454–459PubMedGoogle Scholar
  168. Miller CJ, Marthas M, Torten J et al (1994) Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J Virol 68:6391–6400PubMedGoogle Scholar
  169. Miller CJ Lu Y Roberts B et al (1997) Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J Virol 71:1911–1921Google Scholar
  170. Mills KH Page M, Chan WL et al (1992) Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins. J Med Primatol 21:50–58PubMedGoogle Scholar
  171. Montefiori DC, Coliman RG, Fouts TR et al (1998) Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J Virol 72:1886–1893PubMedGoogle Scholar
  172. Moore JP Ho DD (1995) HIV-1 neutralization:the consequences of viral adaptation to growth on transformed T cells. AIDS 9[Suppl A]:S117–S136PubMedGoogle Scholar
  173. Moore JP Cao Y, Qing L et al (1995) Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 69:101–109PubMedGoogle Scholar
  174. Moore JP, Trkola A, Dragic T (1997) Co-receptors for HIV-1 entry. Curr Opin Immunol 9:551–562PubMedGoogle Scholar
  175. Mortara L, Letourneur F, Gras-Masse H et al (1998) Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J Virol 72:1403–1410PubMedGoogle Scholar
  176. Munoz A, Kirby AJ, He YD et al (1995) Long-term survivors with HIV-1 infection:incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune Defic Syndr Hum Retrovirol 8:496–505PubMedGoogle Scholar
  177. Munoz A, Sabin CA, Phillips AN (1997) The incubation period of AIDS. AIDS 11[Suppl A]:S69–S76PubMedGoogle Scholar
  178. Murali-Krishna K, Altman JD, Suresh M et al (1998) Counting antigen-specific CD8 T cells:a reevaluation of bystander activation during viral infection. Immunity 8:177–187PubMedGoogle Scholar
  179. Murphey-Corb M, Ohkawa S, Davison-Fairburn B et al (1992) A formalin-fixed whole SIV vaccine induces protective responses that are cross-protective and durable. AIDS Res Hum Retroviruses 8:1475–1478PubMedGoogle Scholar
  180. Murphey-Corb M, Ohkawa S, Davison-Fairburn B et al (1992) A formalin-fixed whole SIV vaccine induces protective responses that are cross-protective and durable. AIDS Res Hum Retroviruses 8:1475–1478PubMedGoogle Scholar
  181. Muster T, Guinea R, Trkola A et al (1994) Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 68:4031–4034.PubMedGoogle Scholar
  182. Nara PL Robey WG, Pyle SW et al (1988) Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J Virol 62:2622–2628PubMedGoogle Scholar
  183. Nathanson N, Gonzalez-Scarano F (1989) Human immunodeficiency virus:an agent that defies vaccination. Adv Vet Sci Comp Med 33:397–412PubMedGoogle Scholar
  184. Niedrig M Gregersen JP, Fultz PN et al (1993) Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge. Vaccine 11:67–74PubMedGoogle Scholar
  185. Novembre FJ, Saucier M, Anderson DC et al (1997) Development of AIDS in a chimpanzee infected with human immunodeficiency virus type. J Virol 71:4086–4091PubMedGoogle Scholar
  186. Nyambi PN, Nkengasong J, Peeters M et al (1995) Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. J Infect Dis 172:1228–1237PubMedGoogle Scholar
  187. Nyambi PN, Nkengasong J, Lewi P et al (1996) Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol 70:6235–6243PubMedGoogle Scholar
  188. O’Doherty U, Ignatius R, Bhardwaj N, Pope M (1997) Generation of monocyte- derived dendritic cells from precursors in rhesus macaque blood. J Immunol Methods 207:185–194PubMedGoogle Scholar
  189. Okada E, Sasaki S, Ishii N et al (1997) Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)- expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 159:3638–3647PubMedGoogle Scholar
  190. Oravecz T, Pall M, Norcross MA (1996) Beta-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step. J Immunol 157:1329–1332PubMedGoogle Scholar
  191. Pal R, Garzino-Demo A, Markham PD et al (1997) Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 278:695–698PubMedGoogle Scholar
  192. Palella FJ Jr, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853–860PubMedGoogle Scholar
  193. Paliard X, Lee AY, Walker CM (1996) RANTES, MIP-1 alpha and MIP-1 beta are not involved in the inhibition of HIV-1SF33 replication mediated by CD8+ T-cell clones. AIDS 10:1317–1321PubMedGoogle Scholar
  194. Payne R, Tripp M, Weigle J et al (1964) A new leukocyte isoantigen system in man. Cold Spring Harbor Symp Quant Biol 29:285–295PubMedGoogle Scholar
  195. Perales MA, Schwartz DH, Fabry JA, Lieberman J (1995) A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J Acquir Immune Defic Syndr Hum Retrovirol 10:27–35PubMedGoogle Scholar
  196. Perelson AS, Essunger P, Ho DD (1997) Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS 11[Suppl]:S17–S24PubMedGoogle Scholar
  197. Phanuphak P, Teeratakulpixarn S, Sarangbin S et al (1997) International clinical trials of HIV vaccines:I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac J Allergy Immunol 15:41–48PubMedGoogle Scholar
  198. Picard O, Achour A, Bernard J et al (1992) A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans:evidence for persistent cell-mediated immunity. J Acquir Immune Defic Syndr Hum Retrovirol 5:539–546Google Scholar
  199. Plotkin SA, Mortimer EA (1994) Vaccines, 2nd edn. Saunders, PhiladelphiaGoogle Scholar
  200. Price DA, Goulder PJ, Klenerman P et al (1997) Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 94:1890–1895PubMedGoogle Scholar
  201. Prince AM, Horowitz B, Shulman RW et al (1990) Apparent protection of HIV infection by HIV immunoglobulin given prior to low-dose HIV challenge. In:Brown F, Chanock R, Ginsberg H, Lerner R (eds) Vaccines 90. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 347–351Google Scholar
  202. Prince AM, Reesink H, Pascual D et al (1991) Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses 7:971–973PubMedGoogle Scholar
  203. Purtscher M, Trkola A, Gruber G et al (1994) A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 10:1651–1658PubMedGoogle Scholar
  204. Pushko P, Parker M, Ludwig GV et al (1997) Replicon-helper systems from attenuated Venezuelan equine encephalitis virus:expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389–401PubMedGoogle Scholar
  205. Putkonen P, Thorstensson R, Ghavamzadeh L et al (1991) Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 352:436–438PubMedGoogle Scholar
  206. Putkonen P, Thorstensson R, Cranage M et al (1992) A formalin inactivated whole SIVmac vaccine in Ribi adjuvant protects against homologous and heterologous SIV challenge. J Med Primatol 21:108–112PubMedGoogle Scholar
  207. Putkonen P, Nilsson C, Makitalo B et al (1996) Immunization with live attenuated SIVmac can protect macaques against mucosal infection with SIVsm. In:Brown F, Chanock R, Ginsberg H, Lerner R (eds) Vaccines 96. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 1–5Google Scholar
  208. Reitter JN, Means RE, Desrosiers RC (1998) A role for carbohydrates in immune evasion in AIDS. Nat Med 4:679–684PubMedGoogle Scholar
  209. Richardson TM, Stryjewski BL, Broder CC et al (1996) Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol 70:753–762PubMedGoogle Scholar
  210. Rinaldo CR Jr, Beltz LA, Huang XL et al (1995) Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. AIDS Res Hum Retroviruses 11:481–489PubMedGoogle Scholar
  211. Robey FA Harris-Kelson T, Robert-Guroff M et al (1996) A synthetic conformational epitope from the C4 domain of HIV Gpl20 that binds CD4. J Biol Chem 271:17990–17995Google Scholar
  212. Robey WG, Arthur LO, Matthews TJ et al (1986) Prospect for prevention of human immunodeficiency virus infection:purified 120 kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci USA 83:7023–7027PubMedGoogle Scholar
  213. Rolls MM, Haglund K, Rose J (1996) Expression of additional genes in a vector derived from a minimal RNA virus. Virology 218:406–411PubMedGoogle Scholar
  214. Romagnani S, Del Prete G, Manetti R et al (1994) Role of TH1/TH2 cytokines in HIV infection. Immunol Rev 140:73–92PubMedGoogle Scholar
  215. Rosenberg ES, Billingsley JM, Caliendo AM et al (1997) Vigorous HIV-l-specific CD4+ T cell responses associated with control of viremia. Science 278:1447–1450PubMedGoogle Scholar
  216. Rouaix F, Gras-Masse H, Mazingue C et al (1994) Effect of a lipopeptidic formulation on macrophage activation and peptide presentation to T cells. Vaccine 12:1209–1214PubMedGoogle Scholar
  217. Rovinski B, Haynes JR, Cao SX et al (1992) Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins:implications for development of a cross- protective AIDS vaccine. J Virol 66:4003–4012PubMedGoogle Scholar
  218. Rowland-Jones S, Corrah T, Gallimore A et al (1995) HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1:59–64PubMedGoogle Scholar
  219. Rubbert A, Weissman D, Combadiere C et al (1997) Multifactorial nature of noncytolytic CD8+ T cell-mediated suppression of HIV replication:beta- chemokine-dependent and -independent effects. AIDS Res Hum Retroviruses 13:63–69PubMedGoogle Scholar
  220. Rubinstein A, Goldstein H, Pettoello-Mantovani M et al (1995) Safety and ìmmunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. AIDS 9:243–251PubMedGoogle Scholar
  221. Russell C (1984) Virus discovery could lead to test for AIDS. The Washington Post, 24 April 1984, section A, p 1Google Scholar
  222. Sabin AB (1992) Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc Natl Acad Sci USA 89:8852–8855PubMedGoogle Scholar
  223. Salmon-Ceron D, Excler JL, Sicard D et al (1995) Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res Hum Retroviruses 11:1479–1486PubMedGoogle Scholar
  224. Sasaki S, Sumino K, Hamajima K et al (1998) Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J Virol 72:4931–4939PubMedGoogle Scholar
  225. Sattentau QJ, Moore JP (1995) Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 182:185–196PubMedGoogle Scholar
  226. Schneider J, Gilbert SC, Blanchard TJ et al (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4:397–402PubMedGoogle Scholar
  227. Schrager LK, Young JM, Fowler MG et al (1994) Long-term survivors of HIV-1 infection:definitions and research challenges. AIDS 8[Suppl 1]:S95–S108Google Scholar
  228. Schwartz DH, Gorse G, Clements ML et al (1993) Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1 HIB rgpl20 subunit vaccine. Lancet 342:69–73PubMedGoogle Scholar
  229. Sheppard HW, Lang W, Ascher MS et al (1993) The characterization of non- progressors:long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 7:1159–1166PubMedGoogle Scholar
  230. Shibata R, Hoggan MD, Broscius C et al (1995) Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo. J Virol 69:4453–4462PubMedGoogle Scholar
  231. Shibata R, Seimon C, Cho MW et al (1996) Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1. J Virol 70:4361–4369PubMedGoogle Scholar
  232. Shibata R, Martin MA, Desrosiers RC et al (1997) Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J Virol 71:8141–8148PubMedGoogle Scholar
  233. Shiver JW, Davies ME, Yasutomi Y et al (1997) Anti-HIV env immunities elicited by nucleic acid vaccines. Vaccine 15(8):884–887PubMedGoogle Scholar
  234. Smith AD, Geisler SC, Chen AA et al (1998) Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1. J Virol 72:651–659PubMedGoogle Scholar
  235. Smith TF, Srinivasan A, Schochetman G et al (1988) The phylogenetic history of immunodeficiency viruses. Nature 333:573–575PubMedGoogle Scholar
  236. Stanhope PE, Clements ML, Siliciano RF (1993) Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gpl60 subunit vaccine. J Infect Dis 168:92–100PubMedGoogle Scholar
  237. Steimer KS, Haigwood NL (1991) Importance of conformation on the neutralizing antibody response to HIV-1 gpl20. Biotechnol Ther 2:63–89PubMedGoogle Scholar
  238. Sutter G, Moss B (1995) Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand 84:195–200PubMedGoogle Scholar
  239. Trkola A, Pomales AB, Yuan H et al (1995) Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 69:6609–6617PubMedGoogle Scholar
  240. Trkola A, Purtscher M, Muster T et al (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gpl20 glycoprotein of human immunodeficiency virus type 1. J Virol 70:1100–1108PubMedGoogle Scholar
  241. Trkola A, Ketas T, Kewalramani VN et al (1998) Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol 72:1876–1885PubMedGoogle Scholar
  242. Tyler DS, Stanley SD, Nastala CA et al (1990) Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 144:3375–3384PubMedGoogle Scholar
  243. van Cott TC (1997) Protection of rhesus macaques from homologous and heterologous SHIV challenge using oligomeric gpl40. In:Girard M, Dodet B (eds) Retroviruses of human AIDS and related animal diseases:11e Colloque des “Cent Gardes.” Fondation Marcel Merieux, Lyon, France, pp 199–208Google Scholar
  244. van Cott TC, Bethke FR, Burke DS et al (1995a) Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol 155:4100–4110Google Scholar
  245. van Cott TC, Polonis VR, Loomis LD et al (1995b) Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses 11:1379–1391Google Scholar
  246. van der Burg SH, Klein MR, Pontesilli O et al (1997) HIV-1 reverse transcriptase- specific CTL against conserved epitopes do not protect against progression to AIDS. J Immunol 159:3648–3654PubMedGoogle Scholar
  247. Vijh-Warrier S, Pinter A, Honnen WJ, Tilley SA (1996) Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gP120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J Virol 70:4466–4473PubMedGoogle Scholar
  248. Vijh-Warrier S, Pinter A, Honnen WJ, Tilley SA (1996) Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gP120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J Virol 70:4466–4473PubMedGoogle Scholar
  249. Vujcic LK, Quinnan GV Jr (1995) Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res Hum Retroviruses 11:783–787PubMedGoogle Scholar
  250. Wadman M (1998) Ex-UN AIDS chief is blasted for remarks on vaccine strategy. Nature 392:527–528PubMedGoogle Scholar
  251. Walker BD, Plata F (1990) Cytotoxic T lymphocytes against HIV. AIDS 4:177–184PubMedGoogle Scholar
  252. Walker BD, Chakrabarti S, Moss B et al (1987) HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328:345–348PubMedGoogle Scholar
  253. Walker CM (1993) Non-cytolytic control of HIV replication by CD8+ T cells. Semin Immunol 5:195–201PubMedGoogle Scholar
  254. Walker CM, Moodv DJ, Stites DP, Levy JA (1986) CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563–1566PubMedGoogle Scholar
  255. Walker MC, Fast PE (1994) Clinical trials of candidate AIDS vaccines. AIDS 8 [Suppl]:213–236Google Scholar
  256. Warren JT Levinson M A (1997) Preclinical AIDS vaccine development:formal survey of worldwide HIV, SIV and SHI V in vivo challenge studies in nonhuman primates. J Med Primatol 26:63–81PubMedGoogle Scholar
  257. Weber J Fenyo EM, Beddows S et al (1996) Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol 70:7827–7832PubMedGoogle Scholar
  258. Wei X, Ghosh SK, Taylor ME et al (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117–122PubMedGoogle Scholar
  259. Weiss RA, Clapham PR, McClure M, Marsh M (1989) The CD4 receptor for the AIDS virus. Biochem Soc Trans 17:644–647PubMedGoogle Scholar
  260. Wintsch J, Chaignat CL, Braun DG et al (1991) Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J Infect Dis 163:219–225PubMedGoogle Scholar
  261. Wiviott LD, Walker CM, Levy JA (1990) CD8+ lymphocytes suppress HIV production by autologous CD4+ cells without eliminating the infected cells from culture. Cell Immunol 128:628–634PubMedGoogle Scholar
  262. Wrin T Crawford L, Sawyer L et al (1994) Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 7:211–219PubMedGoogle Scholar
  263. Wu S Pascual DW, Lewis GK, Hone DM (1997) Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector. AIDS Res Hum Retroviruses 13:1187–1194PubMedGoogle Scholar
  264. Yang OO Walker BD, Johnson RP et al (1997) Suppression of human immunodeficiency virus type 1 replication by CD8+ cells:evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 71:3120–3128PubMedGoogle Scholar
  265. Yasutomi Y, Koenig S, Woods RM et al (1995) A vaccine-elicited, single viral epitope- specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J Virol 69:2279–2284PubMedGoogle Scholar
  266. Yasutomi Y. Robinson HL, Lu S et al (1996) Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol 70:678–681PubMedGoogle Scholar
  267. Yokoyama S, Chung L, Gojobori T (1988) Molecular evolution of the human immunodeficiency and related viruses. Mol Biol Evol 5:237–251PubMedGoogle Scholar
  268. Zagury D, Lachgar A, Chams V et al (1998) C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 95:3857–3861PubMedGoogle Scholar
  269. Zarling JM, Morton W, Moran PA et al (1986) T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. Nature 323:344–346PubMedGoogle Scholar
  270. Zhang YJ, Fredriksson R, McKeating JA et al (1997) Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. Virology 238:254–264PubMedGoogle Scholar
  271. Zhou X, Berglund P, Rhodes G et al (1994) Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12:1510–1514PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • A. M. Schultz

There are no affiliations available

Personalised recommendations